About this medicine

The dose and duration depend on the indication, age and vulnerability to adverse effects. The oral solution is not a depot injection.

What is this medicine used for?

Selected indications also include severe tics and narrowly defined aggression or psychosis. Paediatric licences have separate age thresholds and prior-treatment requirements.

Paediatric product indications are schizophrenia at 13–17, severe persistent aggression with autism or pervasive developmental disorders at 6–17, and severely impairing tics at 10–17; each requires failure or intolerance of the prior treatments specified in the SmPC. These are not broad licences for childhood behavioural difficulties.

Which warning signs need help?

Fainting or palpitations can signal an abnormal heart rhythm. Fever with rigidity or confusion needs urgent help. New swallowing difficulty requires assessment. Antipsychotic treatment increases mortality risk in older people with dementia.

Both injection types retain serious cardiac and movement risks. The depot contains sesame oil and benzyl alcohol: check allergies and the exact preparation before administration. Once injected, a depot cannot simply be stopped or removed if adverse effects develop.

How do I take it safely?

The adult schizophrenia label describes 2–10 mg daily in one or two doses, with individual adjustment. Older people often require much less. Measure liquid accurately; only dilute as the leaflet directs.

For adult schizophrenia, the maximum is 20 mg/day; doses above 10 mg/day often add movement toxicity without extra benefit. Mania has a different 15 mg/day ceiling. These limits do not apply to frail older people or children. Dilute this solution only with water.

Short-acting haloperidol injection is 5 mg/ml and is given into a muscle by a healthcare professional. Adult uses include rapid control of severe agitation associated with psychosis or bipolar I mania when oral treatment is unsuitable. It is not a depot. Its SmPC recommends intramuscular administration; oral doses are not injection instructions.

Haldol Decanoate contains the equivalent of 50 or 100 mg haloperidol per ml. It is a deep buttock-muscle injection, usually four-weekly, for adult schizophrenia or schizoaffective disorder after stability on oral haloperidol. It is not for immediate symptom control. Conversion and any oral supplementation require the prescribing team.

A checked Teva 5 mg tablet supplies another oral option. Tablet strength does not dictate the starting dose, and a suitable lower-strength or liquid presentation may be needed for small doses. The tablet is not the 5 mg/ml injection; matching numbers do not make the routes interchangeable.

What side effects should I know about?

Restlessness, tremor, stiffness, involuntary movements, sleepiness and dizziness can occur. Report troublesome movements early.

Who needs extra care with this medicine?

Contraindications include Parkinson’s disease, Lewy body dementia and certain heart-rhythm disorders. Correct low potassium or magnesium before treatment.

Can it affect my other medicines?

Other QT-prolonging medicines may be contraindicated. Review all prescribed and non-prescription drugs; alcohol can worsen drowsiness.

Fluoxetine can increase haloperidol exposure; carbamazepine can reduce it. Lithium combinations require vigilance for neurological toxicity. Haloperidol can oppose levodopa’s effects.

What check-ups will I need?

For elderly delirium, MHRA advises baseline ECG and electrolyte correction, repeated assessment, gradual dose changes and the lowest dose for the shortest duration. Monitor movement, swallowing and blood pressure.

The SmPC recommends a baseline ECG for all patients, not only elderly delirium, plus baseline and periodic electrolytes. Follow-up ECG need is assessed individually. Monitor persistent involuntary facial or tongue movements, which can represent tardive dyskinesia.

What about pregnancy, breastfeeding and age?

Pregnancy and breastfeeding require individual assessment. Newborns exposed late in pregnancy may need monitoring. Childhood indications must not be extrapolated from adult treatment.

Teva’s oral tablet label includes restricted paediatric uses after other approaches fail: schizophrenia at 13–17, severe persistent aggression with autism or pervasive developmental disorders at 6–17, and severely impairing tics at 10–17. These do not establish paediatric indications for the acute injection or depot.

What if I miss a dose or want to stop?

Skip a missed dose and take the next as scheduled, without doubling. Planned withdrawal should follow the prescriber’s advice.

How does it work?

Haloperidol changes how brain cells respond to dopamine, a chemical messenger involved in several brain functions. Its main known action is to block dopamine D2 receptors, proteins that receive that particular signal. This is thought to contribute to treatment benefit, although the complete mechanism is not established.

How Brain Cells Communicate

Brain cells release chemical messengers called neurotransmitters, which influence other cells through receptors. Dopamine participates in networks involved in movement, motivation and the interpretation of experiences. Its effects depend on where a message is received, so reducing one kind of dopamine response can affect several functions rather than just one symptom.

What is known: Dopamine messages have different roles in different networks of cells.

What remains uncertain: A single dopamine pathway cannot explain everything a person is experiencing.

Dopamine: D2 receptor

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Cell response: The arrow represents a signaling response, not movement through a pore.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Cell response

    The arrow represents a signaling response, not movement through a pore.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Dopamine can activate d2 receptor and change signaling in the cell.

Dopamine messages have different roles in different networks of cells. Simplified illustration of the process; individual responses vary.
About this illustration

Nerve-cell signal; Receptor action; Network activity. A single dopamine pathway cannot explain everything a person is experiencing.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

Haloperidol acts as an antagonist at D2 receptors: it occupies these receiving sites and reduces their activation by dopamine. D2 identifies one member of the dopamine receptor family. Blocking this action can also affect movement and increase prolactin, a hormone, or chemical message carried in the blood, that helps control milk production. These effects illustrate why the same receptor action can contribute to both wanted and unwanted changes.

What is known: Haloperidol reduces activation of dopamine D2 receiving sites.

What remains uncertain: The amount of receptor blocking does not provide an exact forecast of benefit or side effects.

Haloperidol: D2 receptor

A receptor with natural messenger and a separate terracotta medicine symbol above the membrane; intracellular proteins illustrate the downstream signaling context. Dopamine: A messenger can change signaling through its receptor. D2 receptor: This receptor symbol identifies a function, not a molecular structure. Haloperidol: activation opposed: The crossbar marks opposition to receptor activation, not permanent closure.
  1. Dopamine

    A messenger can change signaling through its receptor.

  2. D2 receptor

    This receptor symbol identifies a function, not a molecular structure.

  3. Haloperidol: activation opposed

    The crossbar marks opposition to receptor activation, not permanent closure.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Haloperidol antagonizes dopamine D2 receptors. This may contribute to antipsychotic effects, but the complete therapeutic mechanism is not established.

Haloperidol reduces activation of dopamine D2 receiving sites. Simplified illustration of the process; individual responses vary.
About this illustration

Medicine; Molecular actions; Clinical effects. The amount of receptor blocking does not provide an exact forecast of benefit or side effects.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

The liver processes haloperidol through several chemical reactions, including ones involving CYP3A4 and CYP2D6, enzymes that help break down medicines. How a product delivers the medicine matters too: tablets and short-acting injections differ from haloperidol decanoate, a depot injection designed to release medicine slowly from a muscle. These delivery systems change exposure, meaning the amount of active medicine present over time, rather than creating a different main receptor target. A long release period can also mean changes in the body unfold gradually.

What is known: Both liver processing and the delivery system affect how long haloperidol remains available.

What remains uncertain: Different forms have their own instructions and cannot be understood from the shared drug name alone.

How the process works

  1. Formulation
  2. Drug exposure
  3. Benefit and harm
Both liver processing and the delivery system affect how long haloperidol remains available. Simplified illustration of the process; individual responses vary.
About this illustration

Formulation; Drug exposure; Benefit and harm. Different forms have their own instructions and cannot be understood from the shared drug name alone.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Movement effects can impair swallowing. In frail older people this can increase aspiration risk, while postural blood-pressure falls can contribute to falls.

How does my body process it?

The liver metabolises haloperidol, including through CYP3A4 and CYP2D6. Age and interacting medicines can alter exposure.

How do treatment options differ?

Oral liquid allows measured doses but does not eliminate cardiac or movement risks. Injection and tablet products need separate prescribing checks.

A closer look at the science

It is a butyrophenone antipsychotic. Dopamine blockade also contributes to movement problems and raised prolactin.

Haloperidol is a butyrophenone derivative. Lactate is a salt; decanoate is a long-chain ester used for depot delivery.

Chemical formula: C21H23ClFNO2

The formula and image depict neutral haloperidol, not the lactate salt or decanoate ester. Formulation changes release, not merely the printed name.

PubChem 2D depiction of neutral haloperidol; salt components omitted.
NCBI PubChem CID 3559. Lines are bonds; unlabeled corners are carbon and many hydrogen atoms are omitted. This neutral-parent drawing is connectivity, not a binding pose.

Parent connectivity only; salt and ester modifications are not shown.

How was this medicine developed?

This oral-solution record dates its first authorisation to June 1989. MHRA reiterated elderly-delirium precautions in December 2021.

Sources and References

  1. Haldol 2 mg/ml oral solution — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Haldol 2 mg/ml oral solution — UK patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Haloperidol: risks in elderly patients treated for acute delirium

    Scope: United Kingdom.

  4. Haldol Decanoate 50 mg/ml and 100 mg/ml solution for injection — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  5. Haloperidol 5 mg/ml solution for injection — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  6. Haloperidol 5 mg tablets — Teva UK SmPC

    Scope: United Kingdom; named product information.

  7. Haloperidol tablets: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Clinical Pharmacology..

  8. Haldol Decanoate (haloperidol decanoate): prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 5.14 Hyperprolactinemia; 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics..

  9. Haloperidol: verified neutral parent, PubChem CID 3559

    Scope: International chemical reference.

  10. NIMH: Understanding psychosis
  11. Tardive dyskinesia: MedlinePlus Medical Encyclopedia
  12. NIMH: Mental Health Medications

Shared scientific background. US product pharmacology and chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top